Upcoming events in Boston and San Diego build on the success of the conference in London
Events organiser SMI is gearing up for two annual conferences to take place in the US.
Pharmaceutical Microbiology East Coast is scheduled on 10-11 April 2019 at Battery Wharf Hotel in Boston. The conference is chaired by James Drinkwater, Chairman of the Pharmaceutical and Healthcare Sciences Society.
In its second year running, the event will welcome experts to discuss and analyse the latest advances and challenges within the industry, including the revision of Annex 1, data integrity considerations for conventional and rapid microbiology methods, arising issues with environmental monitoring and perspectives on automated endotoxin testing and process automation.
The Pharmaceutical Microbiology West Coast will follow on 5-6 June 2019. The event will be held at the Hyatt Regency Mission Bay, in San Diego. This will be the third outing of the conference in California.
Chaired by Ziva Abraham, Microrite CEO, the programme also features relevant topics for industry professionals, including risk-based approaches to aseptic processing, methods of contamination prevention, creating risk-based environmental monitoring programmes, water monitoring and treatment.
Both US events build on the success of the Pharmaceutical Microbiology UK. The conference drew to a close on 22 January with positive feedback from delegates and exhibitors alike. It attracted six sponsors, including DuPont as a Gold sponsor partner, and a total of 80 attendees over two days.
Freida Choy, Global Account Manager, DuPont, told CT it was the first time that the company had engaged and sponsored this kind of event. "We had a great opportunity to share our insights and knowledge about how risk management and contamination control can be supported by the choices of protective materials," she said.
Choy continued: "Our first experience is encouraging and we will evaluate in the coming months how we can further develop joint subjects of interest for sharing and strengthening product and patient safety.
"In all cases, we have learned a lot about the hot subjects in pharma manufacturing from the microbiological point of view. We got new inspirations for further upgrading our product data packages to better serve this science-driven pharma industry and, even better, we see opportunities to join forces with other players in the value chain."
SMI has already confirmed that Pharmaceutical Microbiology UK will return to London in January 2020.